This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.
Participation in the study will last about 61 weeks.
Have type 2 diabetes treated with diet and exercise and metformin and/or basal insulin
Have HbA1c > 6.5% to ≤ 11.0% at screening
Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of >85th percentile
Have type 1 diabetes
After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
Have had at least one episode of severe hypoglycemia and/or at least one episode of hypoglycemic unawareness within the last 6 months before screening
Have a history of pancreatitis or gallbladder disease
Parallel
Orforglipron
DrugAdministered orally
Dulaglutide
DrugAdministered SC
Change from Baseline in Hemoglobin A1c (HbA1c)
Change from Baseline in HbA1c
Percentage of Participants with HbA1c ≤6.5%
Percent Change from Baseline in Body Mass Index (BMI)
Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
